The Proof of the Pudding Is in the Eating: Real-Life Intra- and Extrapulmonary Impact of Elexacaftor/Tezacaftor/Ivacaftor
Respiration · 24.01.2025 · 104 (6) · 388-396
DOI: 10.1159/000543009 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Respiration, online erschienen am 24.01.2025. Verfasst von Stefanie Vincken und 6 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Division, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Hauptthemen laut MEDLINE: Chloride Channel Agonists, Cystic Fibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Introduction
Elexacaftor/tezacaftor/ivacaftor (ETI) has shown significant improvements in pulmonary and nutritional status in persons with cystic fibrosis (pwCF). Less is known about the extrapulmonary impact of ETI and effects on airway microbiology, lung clearance index (LCI), and fraction of exhaled nitric oxide (FeNO).
Methods
This is a multicenter prospective observational trial, including 79 pwCF ≥18 years eligible for ETI. Assessments were done at the initiation of and 3 and 6 months into treatment with ETI. Outcomes included forced expiratory volume in 1 s (FEV1), LCI, FeNO, sputum or cough swab culture, body mass index (BMI), cystic fibrosis questionnaire-revised respiratory domain (CFQ-R RD), sinonasal outcome test-22 (SNOT-22), general anxiety disorder-7 (GAD-7), patient health questionnaire-9 (PHQ-9), fecal elastase-1 (FE-1), adherence to baseline therapies, exacerbation rate, and adverse events.
Results
Our cohort included 79 pwCF (31 ± 11(SD) years) with a baseline ppFEV1 of 68 ± 23. Forty-two (53%) pwCF were previously treated with a CFTR modulator. In the entire study group, there were significant improvements from baseline in ppFEV1, LCI, FeNO, annualized exacerbation rate, BMI, CFQ-R RD, and SNOT-22 (p < 0.05 for all). Airway culture positivity for methicillin-susceptible Staphylococcus aureus and Pseudomonas aeruginosa also decreased during the study period. There was no significant change in FE-1, GAD-7, or PHQ-9. Adherence to dornase alfa and hypertonic saline decreased.
Conclusion
ETI treatment led to significant improvements in respiratory and nutritional status, alongside a decrease in adherence to chronic supportive therapies. We did not observe any significant changes in exocrine pancreas function or in questionnaire scores for depression and anxiety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Respiratory Division, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
- Department of Psychology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
- Respiratory Division, CHU Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Zitieren
APA
Vincken, S., Verbanck, S., Braun, S., Buyck, N., Zienebergh, C., Knoop, C., & Vanderhelst, E. (2025). The Proof of the Pudding Is in the Eating: Real-Life Intra- and Extrapulmonary Impact of Elexacaftor/Tezacaftor/Ivacaftor. Respiration, 104(6), 388-396. https://doi.org/10.1159/000543009
Vancouver
Vincken S, Verbanck S, Braun S, Buyck N, Zienebergh C, Knoop C, et al. The Proof of the Pudding Is in the Eating: Real-Life Intra- and Extrapulmonary Impact of Elexacaftor/Tezacaftor/Ivacaftor. Respiration. 2025;104(6):388-396. doi:10.1159/000543009
BibTeX
@article{Vincken2025,
author = {Vincken, Stefanie and Verbanck, Sylvia and Braun, Sue and Buyck, Nathalie and Zienebergh, Cindy and Knoop, Christiane and Vanderhelst, Eef},
title = {The Proof of the Pudding Is in the Eating: Real-Life Intra- and Extrapulmonary Impact of Elexacaftor/Tezacaftor/Ivacaftor},
journal = {Respiration},
year = {2025},
volume = {104},
number = {6},
pages = {388--396},
doi = {10.1159/000543009}
}
EUVIMED